Twist Bioscience Expects Q4 2024 Revenues Of $82M-$83M Versus Prior Guidance Of $77M-$80M And Consensus Of $79.602M
Author: Benzinga Newsdesk | August 02, 2024 07:37am
For the fourth quarter of fiscal year 2024, Twist provided the following financial guidance:
- Total revenue of approximately $82 million to $83 million compared to the previous estimate of $77 million to $80 million
- Gross margin of approximately 44% compared to the previous estimate of 43-44%
- Adjusted EBITDA loss of $20 million
Posted In: TWST